Osteocalcin in serum, saliva and gingival crevicular fluid : their relation with periodontal treatment outcome in postmenopausal women by Bullón, Pedro et al.
E193
Med Oral Patol Oral Cir Bucal 2007;12:E193-7.                                                                  � Osteocalcin, osteoporosis, periodontitis                                                        Med Oral Patol Oral Cir Bucal 2007;12:E193-7.                                                                 � Osteocalcin, osteoporosis, periodontitis
© Medicina Oral S.L. Email: medicina@medicinaoral.com
Osteocalcin in serum, saliva and gingival crevicular fluid: their relation 
with periodontal treatment outcome in postmenopausal women
Pedro Bullon 1, Lucy Chandler 1, Juan J. Segura Egea 1, Ramón Perez Cano 2, Angel Martinez Sahuquillo 1
(1) Periodontics Department
(2) Medicine Department, School of Medicine, University of Sevilla
Correspondence:
Prof. Pedro Bullón Fernández




Accepted: 25-03-2007 Bullon P, Chandler L, Segura-Egea JJ, Perez-Cano R, Martinez-Sahu-
quillo A. Osteocalcin in serum, saliva and gingival crevicular fluid: their 
relation with periodontal treatment outcome in postmenopausal women. 
Med Oral Patol Oral Cir Bucal 2007;12:E193-7.
© Medicina Oral S. L. C.I.F. B 96689336 - ISSN 1698-6946
ABSTRACT
Background. Osteocalcin levels have been postulated as a marker of inhibition of bone formation. The aim of the pre-
sent study was to assess plasma, saliva and GCF levels of osteocalcin and correlate them with periodontal treatment 
outcome in postmenopausal women.
Methods. Thirty-nine postmenopausal women (57.8 ±8.5 years old) were recruited for the study. Periodontal examination 
of all women was carried out and plaque, bleeding on probing, probing depth (PD), and clinical attachment level (CAL) 
were recorded. Serum, saliva and gingival crevicular fluid osteocalcin were measured. Then, periodontal treatment was 
carried out. Six months after the first appointment a second periodontal examination was carried out. 
Results. Mean PD and mean CAL decreased significantly at second appointment in the group with serum osteocalcin 
concentration < 10 ng/ml (15.8 ±15.8% and 15.3 ± 21.2% respectively; p < 0.05). Mean PD decreased significantly at 
second appointment in the groups with saliva osteocalcin concentration < 3 ng/ml (17.1 ± 15.9%; p < 0.05) and 3 – 7 
ng/ml (16.2 ± 18.1%; p < 0.05).
Conclusions. Low serum osteocalcin concentration is associated to a significantly higher percentage of decrease in PD 
and CAL after periodontal treatment in postmenopausal women. Low saliva osteocalcin concentrations are significantly 
associated to a higher percentage of decrease in PD.
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RESUMEN
Antecedentes. Los niveles de osteocalcina se han propuesto como marcador de la inhibición de la formación ósea. El 
propósito de este trabajo es determinar las concentraciones de osteocalcina en plasma, saliva y fluido crevicular corre-
lacionándolo con el resultado del tratamiento periodontal en mujeres postmenopáusicas. 
Pacientes y métodos. El estudio se realizó en treinta y nueve mujeres postmenopáusicas (57.8 ±8.5 años de edad). El examen 
periodontal incluyó el control de placa, el sangrado al sondaje, la profundidad de sondaje (PS) y la pérdida de inserción 
(CAL). Se determinaron los niveles de osteocalcina en suero, saliva y fluido crevicular. A continuación se llevó a cabo el 
tratamiento periodontal. Pasados seis meses tras la primera cita se llevó a cabo un segundo examen periodontal. 
Resultados. Las medias de la PS y del CAL disminuyeron  significativamente en el segundo examen periodontal en el 
grupo de mujeres con osteocalcina en suero < 10 ng/ml (15.8± 15.8% y 15.3± 21.2%, respectivamente; p < 0.05). La PS 
media disminuyó significativamente en el segundo exámen en los grupos con concentraciones de osteocalcina en saliva 
< 3 ng/ml (17.1± 15.9%; p < 0.05) y 3 – 7 ng/ml (16.2 ± 18.1%; p < 0.05).
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INTRODUCTION
Periodontitis is an inflammatory disease usually leading to 
loss of bone. In periodontitis, there is an increased turnover 
of alveolar bone although there may be a dominance of 
bone resorption over bone formation, leading to alveolar 
bone loss and loss of  attachment (1). Increase in bone 
resorption due to gonadal reasons, and accelerated loss of 
bone in the first decade after menopause appear to be the 
main pathogenic factors in women (2).
Serum osteocalcin is presently considered a valid marker of 
bone turnover when resorption and formation are coupled 
and a specific marker of bone formation when formation 
and resorption are uncoupled (3). Gingival crevicular fluid 
(GCF), which is an exudate that can be harvested from the 
sulcus or periodontal pocket, has been regarded as a promi-
sing medium for the detection of periodontal disease activity 
(4,5). So, the majority of new diagnostic tests for periodontal 
disease utilize GCF ( 6,7). Several investigations on osteo-
calcin levels in GCF from patients with periodontitis (8-12) 
have been reported, suggesting that osteocalcin levels in 
GCF may reflect inflammation at diseased sites and there 
has been recent interest in osteocalcin as a potential mar-
ker of bone turnover in periodontal disease (1,3). But the 
role of osteocalcin in periodontal disease progression and 
periodontal treatment outcome is still unclear. 
The aim of the present study was to assess plasma, saliva and 
GCF levels of osteocalcin and correlate it with periodontal 




Subjects selection and clinical examination
For 2 years all the periodontally diseased women with more 
than one year after menopausal attended in our Dental 
School, were proposed to participate in the study. The 
initial sample consisted of 81 women but the final sample 
was reduced to 39 women because some did not follow the 
treatment in their totality and others did not return to re-
vision. Our protocol and consent forms were approved by 
the Committee of Ethics and Research of the University 
Hospital “Virgen Macarena”. Periodontal examination of 
all women was carried out and the following measurements 
were recorded: a) O´Leary plaque index (13), b) Van der 
Velden bleeding on probing index (14), c) probing depth 
(PD): measured from the gingival margin to the most apical 
penetration of the probe, and d) recession was measured, 
from the cemento-enamel junction to the gingival margin. 
Clinical attachment level (CAL) was calculated adding re-
cession to PD.  PD and CAL were assessed at six sites per 
tooth: mesial edge, midtooth, and distal edge on both facial 
and lingual sides. Women were classified as periodontally 
diseased according to the criteria established by Machtei 
(15): the clinical entity of periodontitis is suggested based 
on the presence of CAL ≥ 6 mm in two or more teeth and 
one or more sites with PD ≥ 5 mm.  Moreover, all the wo-
men had to meet the following criteria: at least 12 months 
since the last menstrual period, at least three functional 
teeth, no taking hormone therapy, no receiving medical 
treatment influencing the bone metabolism, no suffering 
any metabolic diseases, and without densitometric diagnosis 
of osteoporosis. 
In the first appointment some general data were recorded: 
age, age at menopause, years since menopause, and cigarette 
smoking. Samples for the determination of  osteocalcin 
concentration in serum, saliva and gingival crevicular fluid 
were taken, and a densitometry was prescribed. Following 
baseline examination, all patients were instructed in oral 
hygiene and scaling and root planning was performed under 
local anaesthesia in 4 sessions.
Six months after the first appointment a second periodontal 
examination of all patients was carried out. Samples for the 
determination of osteocalcin concentration in serum, saliva 
and gingival crevicular fluid were also taken. Percentages 
of  variation of  PD and CAL between the first and the 
second appointments were calculated by subtracting both 
determinations and expressing this value as percentage of 
the first determination. 
Sample collection and analytical determinations
Blood was centrifuged to obtained plasma. Gingival cre-
vicular fluid (GCF) sampling was performed based on the 
previously method described by Nomura et al. (16,17). 
Each subject was monitored at 4 sites in the upper incisors 
teeth. The sites always were PD ≥ 5 mm. After isolation 
from saliva, the area around each site sampled was dried 
and supragingival plaque removed. GCF was collected for 
2 minutes using four strips (20 x 4 mm) of Whatmann 1 
paper (Whatmann Lab Sales Ltd, Maidstone, Kent, UK). 
Each strip was placed gently into the gingival crevice until 
slight resistance was felt, and GCF volume was collected. 
The GCF absorbed (µl) / wet area (mm2) in the strip paper 
was calculated by comparing it to the amount of a standard 
plasma containing a low concentration of 125I used as a 
tracer that the strip can absorb, similar to what has been 
described for blood specimens (18,20). A saliva sample was 
also collected from the sublingual zone with the same paper 
strips. The plasma, saliva and GCF samples were placed in 
a microcentrifuge tube and vortexed in 200 µL of extraction 
buffer consisting of 0.5 NaCl, 50mM Tris-HCL (ph 7.4), 5 
mM CaCl2 and 0.05% Brij 35 (polyoxyethylene lauryl ether), 
following the method described by Lee et al. (20). 
Conclusiones. Los niveles bajos de osteocalcina en suero se asocian significativamente a un  mayor porcentaje de dismi-
nución de la PS y del CAL tras el tratamiento periodontal en mujeres postmenopáusicas. Las bajas concentraciones de 
osteocalcina en saliva se asociaron significativamente a un mayor porcentaje de disminución de la PS.
Palabras clave: Osteocalcina, osteoporosis, periodontitis.
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Osteocalcin assay
Osteocalcin measurements in serum, saliva and GCF were 
made using an electrochemiluminescence technique descri-
bed previously (12). 
Statistical analysis
Data are expressed as means ± standard deviation. Diffe-
rences between groups in normally continuous variables 
were assessed by analysis of variance (ANOVA), using the 
Bonferroni test to establish differences between groups. 
Discrete variables were analysed by mean of the frequencies 
distribution.
RESULTS
The mean age of the 39 women was 57.8 ± 8.5 years. Only 
four of them were smoker. Mean menopausal age was 48.3 
± 5.7. Mean number of years since menopause was 9.61 
± 8.1. 
Mean PD, mean CAL, and mean BOP decreased significan-
tly after periodontal treatment (p < 0.01) (Table 1). There 
were no significant differences in the percentage of sites with 
plaque between first and second appointment.
Variations in PD and CAL were analysed according to 
serum osteocalcin levels (Table 2). In two patients it was 
not possible to obtain serum samples. Patients were clas-
sified in two groups according to the osteocalcin level in 
serum: a) <10 ng/ml osteocalcin concentration (n = 29); 
and b) > 10 ng/ml osteocalcin concentration (n = 8). PD 
and CAL were significantly higher both in the first and 
second appointments in the group with serum osteocalcin 
concentration > 10 ng/ml (p < 0.05). Mean PD and mean 
CAL decreased significantly at second appointment, after 
periodontal treatment, in the group with serum osteocalcin 
concentration < 10 ng/ml (-15.8 ± 15.8% and -15.3 ± 21.2% 
respectively; p < 0.05). In the group with serum osteocalcin 
concentration > 10 ng/ml mean PD decreased significantly 
at second appointment (-17.6 ± 13.3 %; p < 0.05) but CAL 
did not differ (-17.4 ± 29.7%; p >0.05). There were not found 
significant differences between the two groups in PD and 
CAL percentages of variation between the first and second 
appointments.
Variations in PD and CAL were analysed according to 
GCF osteocalcin levels (Table 3). Patients were classified 
in three groups according to the osteocalcin level in GCF: 
a) <12 ng/ml osteocalcin concentration (n = 10); b) 12 – 30 
ng/ml (n = 9); and c) > 30 ng/ml osteocalcin concentration 
(n = 20). There were not significant differences between the 
three groups in PD and CAL neither in the first nor in the 
second appointments. Mean PD and mean CAL did not 
vary significantly at second appointment, after periodontal 
treatment, in the three groups. PD and CAL percentages of 
variation between the first and second appointment did not 
differ significantly in the three groups.
Variations in PD and CAL were analysed according to sa-
liva osteocalcin levels (Table 4). Patients were classified in 
three groups according to the osteocalcin level in saliva: a) 
< 3 ng/ml osteocalcin concentration (n = 10); b) 3-7 ng/ml 
(n = 20); and c) > 7 ng/ml osteocalcin concentration (n = 
9). There were not significant differences between the three 
groups in PD and CAL neither in the first nor in the second 
appointments. Mean PD decreased significantly at second 
appointment, after periodontal treatment, in the groups 
with saliva osteocalcin concentration < 3 ng/ml (-17.1 ± 
15.9%; p < 0.05) and 3 – 7 ng/ml (-16.2 ± 18.1%; p < 0.05). 
PD and CAL percentages of variation between the first 
and second appointment did not differ significantly in the 
three groups.





PD (mm) 2.6 � 0.5 2.2 � 0.4 < 0.01 
CAL (mm) 3.5 � 1.1 3.0 � 0.8 < 0.01 
BOP (%) 73.3 � 17.7 56.9 � 20.6 < 0.01 
Plaque (%) 67.0 � 30.1 71.2 � 23.2 > 0.05 
<10 ng/ml     
n = 29 
<10 ng/ml 
n = 8 
p
1st - Mean 
PD (mm) 
2.53 � 0.4 3.01 � 0.5 0.01
2nd - Mean 
PD (mm) 
2.13 � 0.4 2.48 � 0.4 0.03
1-2 PD 
variation (%) 
-15.8�15.8** - 17.6�13.3** > 0.05 
1st - Mean 
CAL (mm) 
3.33 � 0.8 4.38 � 1.6 0.01
2nd - Mean 
CAL (mm) 





-17.4 � 29.7* > 0.05 
Table 1. Clinical characteristics of  periodontally diseased 
postmenopausal women in the first and second appointments 
(mean ± SD).
Table 2. Variations in PD and CAL between the first and second 
appointments and their relation with serum osteocalcin concentrations 
(ng/ml). 
*1st vs 2nd appointment p > 0.05.
**1st vs 2nd appointment p < 0.05.
PD: Probing depth.
CAL: Clinical attachment level.
PD: Probing depth. 
BOP: Bleeding on probing index.
CAL: Clinical attachment level.
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< 12 ng/ml 
n = 10 
12 – 30 ng/ml   
n = 9 
>30 ng/ml     
n = 20 
p
1st - Mean 
PD (mm) 
2.35 � 0.3 2.61 � 0.5 2.79 � 0.5 0.06
2nd - Mean 
PD (mm) 
2.08 � 0.3 2.31 � 0.4 2.22 � 0.4 0.47
1-2 PD 
variation (%) 
-11.5 � 12.8* -11.5 � 19.2* -20.4 � 17.9* >0.05
1st - Mean 
CAL (mm) 
3.24 � 1.4 3.60 � 0.8 3.66 � 1.0 0.58
2nd - Mean 
CAL (mm) 
2.86 � 1.3 3.09 � 0.5 2.97 � 0.7 0.84
1-2 CAL 
variation (%) -11.7 � 43.2* -14.2 � 13.9* -18.8 � 13.7* >0.05
< 3 ng/ml          
n = 10
3 - 7 ng/ml         
n = 20
> 7 ng/ml 
n = 9
p
1st - Mean PD (mm) 2.51 � 0.4 2.77 � 0.5 2.46 � 0.5 0.19
2nd - Mean PD (mm) 2.08 � 0.4 2.32 � 0.4 2.08 � 0.4 0.18
1-2 PD 
variation (mm) 
     17.1 � 15.9** 16.2 � 18.1** 15.4 � 20.3* >0.05
1st - Mean CAL 
(mm)
3.10 � 0.6 3.87 � 1.2 3.29 � 0.8 0.12
2nd - Mean CAL 
(mm)
2.57 � 0.6 3.25 � 1.0 2.81 � 0.4 0.09
1-2 CAL variation 
(%) 17.1 � 19.4* 16.0 � 31.0* 14.6 � 24.3* >0.05
Table 3. Variations in PD  and CAL between the first and second appointments and 
their relation with GCF osteocalcin concentrations (ng/ml).
*1st vs 2nd appointment p > 0.05.
**1st vs 2nd appointment p < 0.05.
PD: Probing depth.
CAL: Clinical attachment level.
Table 4. Variations in PD and CAL between the first and second  appointments and 
their relation with saliva osteocalcin concentrations  (ng/ml).
*p > 0.05; **p < 0.05
PD: Probing depth.
CAL: Clinical attachment level.
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DISCUSSION
Using a longitudinal design, the periodontal treatment 
outcome in postmenopausal women and its correlation 
with GCF, saliva and serum osteocalcin concentrations has 
been studied. We showed that low serum osteocalcin con-
centration is associated to a significantly higher percentage 
of decrease in PD and CAL after periodontal treatment in 
postmenopausal women. We also showed that low saliva 
osteocalcin concentrations are significantly associated to a 
higher percentage of decrease in PD.
In a cross-sectional study carried out by Lee et al. (1) in-
cluding 20 patients, no difference in GCF osteocalcin levels 
were observed between sites with and without periodontal 
pockets in the same patient. Recently, Wilson et al. (11) in a 
study including 14 patients without periodontal treatment, 
did not detect osteocalcin in GCF. However, most of these 
studies (1,10) have been carried out in periodontal patients 
and did not compare healthy and diseased subjects, but 
osteocalcin levels in healthy and periodontally affected sites 
in periodontal patients. 
On the contrary, serum osteocalcin concentration correlated 
significantly with the periodontal treatment outcome. The 
use of serum osteocalcin as osteoporosis marker has been 
studied in 295 women over 67 years, without treatment 
with estrogens. The authors (21) conclude that high serum 
osteocalcin levels are associated with fast bone loss, but the 
individual value of this marker is limited. In some animal 
experimental models it has been possible to verify that serum 
osateocalcin levels are determinant of the bone formation 
(22-24) and it has been showed “in vitro” that has a role in 
the bone resorption process (25,26). Nevertheless, we must 
to be in mind that osteocalcin is produced by osteoblasts 
and only a small fraction is secreted directly in the circu-
lation (27).
We can conclude that low serum osteocalcin concentration 
is associated to a significantly higher percentage of decrease 
in PD and CAL after periodontal treatment in postmeno-
pausal women. Low saliva osteocalcin concentrations are 
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